Scholarlink

<p>Device-detected atrial fibrillation (DDAF) occurs in many patients with implanted cardiac pacemakers, defibrillators, devices for cardiac resynchronization treatment and event recorders. These are short, mostly asymptomatic episodes of atrial fibrillation. In episodes with a duration of more than 5–6 min artefacts are very unlikely. The DDAF is associated with an increased risk of thromboembolic events. The effectiveness and safety of oral anticoagulation for DDAF were investigated in two large randomized studies (NOAH-AFNET&#xa0;6 and ARTESIA [<CitationRef CitationID="CR1">1</CitationRef>, <CitationRef CitationID="CR2">2</CitationRef>]). Fortunately, a low rate of ischemic stroke without anticoagulation (ca. 1%/years) was found in both studies. With therapeutic anticoagulation this can be somewhat reduced but severe bleeding becomes more frequent. The preventive effect of early rhythm-maintaining treatment on stroke suggests that the low atrial load in DDAF correlates with the low stroke rate. This position paper of the German Cardiac Society (DGK) presents the current data situation and formulates expert recommendations for the treatment of patients with DDAF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DGK-Positionspapier zum Umgang mit Device-detektiertem Vorhofflimmern (DDAF)

  • 期刊论文

  • 发表日期：

    2025年6月6日

查看全文
  • Tobias Tönnis,
  • Ralf Birkemeyer,
  • David Duncker,
  • Lars Eckardt,
  • Klaus Gröschel,
  • Dominik Linz,
  • Christian Meyer,
  • Sergio Richter,
  • Florian Straube,
  • Arian Sultan,
  • Rolf Wachter,
  • Maura M. Zylla,
  • Paulus Kirchhof

摘要

Device-detected atrial fibrillation (DDAF) occurs in many patients with implanted cardiac pacemakers, defibrillators, devices for cardiac resynchronization treatment and event recorders. These are short, mostly asymptomatic episodes of atrial fibrillation. In episodes with a duration of more than 5–6 min artefacts are very unlikely. The DDAF is associated with an increased risk of thromboembolic events. The effectiveness and safety of oral anticoagulation for DDAF were investigated in two large randomized studies (NOAH-AFNET 6 and ARTESIA [1, 2]). Fortunately, a low rate of ischemic stroke without anticoagulation (ca. 1%/years) was found in both studies. With therapeutic anticoagulation this can be somewhat reduced but severe bleeding becomes more frequent. The preventive effect of early rhythm-maintaining treatment on stroke suggests that the low atrial load in DDAF correlates with the low stroke rate. This position paper of the German Cardiac Society (DGK) presents the current data situation and formulates expert recommendations for the treatment of patients with DDAF.